Review: Proton-pump inhibitor therapy reduces symptoms in nonulcer dyspepsia better than placebo: COMMENTARY

Veldhuyzen Van Zanten, Sander J.
May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p74
Academic Journal
This article reports that the diagnosis of nonulcer dyspepsia (NUD) requires a normal endoscopy result, but this is poorly handled in a study, which reported that proton-pump inhibitor therapy reduces symptoms in nonulcer dyspepsia better than placebo. Before having endoscopy, many patients take acid-suppressive therapy, which can heal ulcers and erosions. Although clinical trials often exclude the use of such medication for 2 to 4 weeks before enrollment, it can take longer for esophagitis or ulcers to recur.


Related Articles

  • Study supports NICE on dyspepsia. Baines, Emma // GP: General Practitioner;5/24/2004, p19 

    Treatment with a proton pump inhibitor (PPI) followed by test-and-treat for Helicobacter pylori is the best strategy for managing patients with dyspepsia, according to Dutch research. The findings support recommendations made by NICE in its draft guidance on the management of chronic dyspepsia,...

  • Picking a PPI: It comes down to cost. Wigle, Patricia R.; Hein, Brad; Ellis, Robert; Austin, Orson; Kiesler, Joseph; Gait, Kimberly A. // Journal of Family Practice;Apr2008, Vol. 57 Issue 4, p231 

    The article offers tips in choosing the right proton pump inhibitor (PPI) for patients with heartburn in the U.S. A 33-year-old man complained about the occurrence of heartburns after he attempted to lose weight and try to exercise to manage his hypertension. To address the problem, it is...

  • Review: Proton-pump inhibitor therapy reduces symptoms in nonulcer dyspepsia better than placebo.  // ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p74 

    This article presents a study, which reports that proton-pump inhibitor (PPI) therapy reduces symptoms in nonulcer dyspepsia (NUD) better than placebo. The study method consisted of randomized controlled trials that compared PPI therapy with placebo, receptor antagonists, prokinetic therapy,...

  • Review: Proton-pump inhibitors alleviate symptoms of functional (nonulcer) dyspepsia but may not be better than H[sub 2]-antagonists. Schwartz, Mark // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p54 

    Compares proton pump inhibitors (PPI) versus placebo, prokinetics or H[sub2]-antagonists in reducing symptoms of functional dyspepsia in adults. Background on dyspepsia; Information on data sources and study selection; Comparison of outcomes which ranged from mild to nonexistent symptoms ...

  • Esomeprazole 40 mg Once a Day in Patients with Functional Dyspepsia: The Randomized, Placebo-Controlled “ENTER” Trial. van Zanten, Sander Veldhuyzen; Armstrong, David; Chiba, Naoki; Flook, Nigel; White, Robert J.; Chakraborty, Bijan; Gasco, Ally // American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p2096 

    OBJECTIVE: The etiologies of functional dyspepsia (FD) are unclear, but in some studies, treatment with a proton pump inhibitor has been beneficial. The objective of this study was to evaluate the efficacy of esomeprazole 40 mg once a day compared to placebo in achieving symptom relief in...

  • Pilot Study of On-Demand Therapy with Pantoprazole 20mg for Long-Term Treatment in Patients with Mild Gastro-Oesophageal Reflux Disease. Scholten, Theo; Pustlauk, Uwe; Sander, Peter; Bohuschke, Martina; Gatz, Gudrun // Clinical Drug Investigation;2005, Vol. 25 Issue 10, p633 

    Background: Few clinical studies have demonstrated the efficacy of proton pump inhibitors (PPIs) as on-demand therapy for the long-term management of patients with mild gastro-oesophageal reflux disease (GORD). On-demand therapy with pantoprazole 20mg may offer an effective strategy for the...

  • Proton Pump Inhibitors: Effective First-Line Treatment for Management of Dyspepsia. David Peura; Jeff Gudmundson; Nancy Siepman; Betsy Pilmer; James Freston // Digestive Diseases & Sciences;Apr2007, Vol. 52 Issue 4, p983 

    Abstract  The aim of this study was to evaluate the reasons for trial exclusion among dyspeptic patients and estimate the proportion that may have benefited from proton pump inhibitor (PPI) therapy. Stringent inclusion criteria for enrollment in two multicenter functional dyspepsia trials...

  • A Cost-Effectiveness Analysis of Prescribing Strategies in the Management of Gastroesophageal Reflux Disease. Gerson, Lauren B.; Robbins, Anthony S.; Garber, Alan; Hornberger, John; Triadafilopoulos, George // American Journal of Gastroenterology;Feb2000, Vol. 95 Issue 2, p395 

    OBJECTIVE: Patients who have uncomplicated gastroesophageal- reflux disease (GERD) typically present with heartburn and acid regurgitation. We sought to determine the cost-effectiveness of H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as first-line empiric therapy for...

  • Dyspepsia management in the millennium: to test and treat or not? Delaney, B.C. // Gut;Jan2003, Vol. 52 Issue 1, p10 

    Examines the cost effectiveness of testing and treating uninvestigated dyspepsia with endoscopy for non-responders compared with empiric proton pump inhibitor (PPI) treatment followed by endoscopy, or with strategies of test and treat followed by empiric PPI, with endoscopy reserved for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics